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Abstract Objective: To undertake a cost-utility analysis
(CUA) of a pharmacy-led self-management programme for
Chronic Obstructive Pulmonary Disease (COPD). Setting:
A single outpatient COPD clinic at the Mater Hospital,
Belfast, Northern Ireland between. Method: CUA alongside
a randomised control trial. The economic analysis used
data from 127 COPD patients aged over 45 years, with an
FEV1 of 30–80% of the predicted normal value. Partici-
pants received either a pharmacy-led education and self-
management programme, or usual care. One year costs
were estimated from the perspective of the National Health
Service and Personal Social Services and quality-adjusted
life years (QALYs) were calculated based on responses to
the EQ-5D at baseline, 6 and 12 months. Main outcome
measure: Cost per QALY gained. Results: The mean dif-
ferences in costs and effects between the self-management
and education programme and usual care were -£671.59
(95 CI%: -£1,584.73 to -£68.14) and 0.065 (95% CI;
0.000–0.128). Thus the intervention was the dominant
strategy as it was both less costly and more effective than
usual care. The probability of the intervention being cost-
effective was 95% at a threshold of £20,000/QALY gained.
Sensitivity analyses indicated that conclusions were robust
to variations in most of the key parameters. Conclusion:
The self-management and education programme was found
to be highly cost-effective compared to usual care. Further
research is required to establish what aspects of self-man-
agement and education programmes have the greatest
impact on cost-effectiveness.
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Impact of findings on practice
• A structured education and self-management pro-
gramme led by clinical pharmacists for patients with
COPD can bring about a reduction in healthcare
resource utilisation and an improvement in health-
related quality of life.
• Education and self-management for patients with
COPD was found to be highly cost-effective compared
with usual care.
Introduction
Chronic obstructive pulmonary disease (COPD) is an
umbrella term for a number of chronic lung conditions
including chronic bronchitis and emphysema. The disease
is typically characterised by airflow obstruction which is
usually progressive and not fully reversible. The airflow
obstruction is generally the result of damage to the airways
brought about by a chronic inflammatory response to (most
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typically) tobacco smoke [1, 2]. Symptoms most com-
monly include cough, phlegm production and shortness of
breath. In severe cases the patient may suffer from frequent
episodes of acute exacerbations or ‘flare-ups’, which con-
tribute towards the overall deterioration of health status and
quality of life [3–5]. COPD is a major cause of morbidity
and mortality in adults with 210 million people diagnosed
worldwide [6]. In the UK, an estimated 900,000 patients
have been diagnosed with the condition, although the
actual number of patients with COPD is believed to be
around 1.5 million [2]. It is expected to be the third leading
cause of death worldwide by 2020 (exceeded only by heart
disease and stroke) [7]. It is difficult to ascertain the true
mortality rate due to COPD, however, it is estimated to
cause approximately 30,000 deaths per year in the UK
[1, 2].
A large-scale international survey ‘‘Confronting COPD
in North America and Europe’’ resulted in comprehensive
information about the impact of COPD on patients,
healthcare and society [8]. Economic analysis of patient
responses to the survey highlighted the substantial eco-
nomic impact of COPD on both the UK healthcare system
and the economy [1]. The average cost per patient per
annum was estimated to be £819.42, with 60% of this cost
(£494.67) attributable to unscheduled care [hospital inpa-
tient stay, accident and emergency visits and unscheduled
visits to a general practitioner (GP) or specialist]. The
authors suggested that the relatively high use of unsched-
uled healthcare resources reported in the survey may reflect
poor disease control with inadequate management of
symptoms and exacerbations.
Self-management is a term applied to any formalised
patient education programme aimed at: teaching the skills
needed to carry out medical regimens specific to the dis-
ease, guide health behaviour change, and provide emo-
tional support for patients in the control of their disease so
that they may live functional lives [9]. There is increasing
awareness that self-management may be an effective
method of managing a range of chronic illnesses [10–13]
including COPD [9, 14]. By providing patients with
information on their condition and how to prevent or
manage exacerbations, their health status may improve and
healthcare resource utilisation decrease. Indeed, the most
recent NICE (National Institute for Health and Clinical
Excellence) clinical guidelines for the management of
COPD recommend that further research be carried out into
the efficacy of such patient focused programmes [2]. The
most recent Cochrane review of self-management educa-
tion interventions of patients with COPD [15] showed that
in general self-management education programmes of
COPD had a positive effect on health care utilisation. A
reduction was observed in hospital admissions and in
doctor and nurse visits, however, an increase in use of
steroid and/or antibiotic courses was observed. The authors
hypothesised that the latter may be due to the educated
patients recognising the symptoms of an exacerbation more
readily and responding to them by the self-initiation of
medication. A small but significant improvement was seen
in health-related quality of life, however, the difference
was not large enough to be considered clinically relevant.
The authors of the review, however, felt that the diversity
of the outcome measures, follow-up periods, COPD-pop-
ulation and interventions used in the studies made it
impossible to draw any firm conclusions regarding the
effectiveness of self-management education for patients
with COPD.
Considering the economic burden of COPD and the
current climate of limited healthcare resources, it is
essential that cost-effective management programmes are
implemented. To date, only a few studies have attempted to
assess the cost-effectiveness of self-management education
in COPD [14, 16, 17]. These studies have differed in the
methodological approach used, the perspective on costs
and outcomes adopted for the analysis and the primary
clinical outcome of interest.
Aim of the study
The aim of the study was to undertake a cost-utility anal-
ysis to establish the cost-effectiveness of a pharmacy-led
education and self-management programme for COPD
compared with usual care.
Methods
The economic evaluation took place alongside a random-
ised control trial (RCT). Ethical approval was obtained
from the Office of Research Ethical Committees for
Northern Ireland (ORECNI: 06/NIR02/23). The full details
of the RCT are presented elsewhere [18], however, in brief,
173 patients were recruited from an outpatient COPD clinic
at the Mater Hospital, Belfast, Northern Ireland between
October 2006 and May 2008 and randomly allocated to
receive either the self-management education programme
or usual care. The randomisation was carried out using the
minimisation method [19]. Patients were included if they
were aged over 45 years with a confirmed diagnosis of
COPD for at least 1 year and an FEV1 of between 30 and
80% of the predicted normal value. Patients with Con-
gestive Heart Failure (CHF), moderate to severe learning
difficulties, severe mobility problems, a terminal illness or
who had attended a pulmonary rehabilitation programme in
the last 6 months were excluded.
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The goal of the self-management education programme
was to increase the patients’ self-efficacy to manage or
avoid breathing difficulty while participating in certain
activities. Intervention patients received a 60 min consul-
tation with a hospital pharmacist at baseline during in
which they were educated individually on COPD, their
prescribed medication, the importance of adherence,
inhaler technique, and the management of COPD symp-
toms including exercise and breathing techniques. A cus-
tomized action plan for acute exacerbations was developed
for each patient which included advice to GPs to provide a
prescription for an antibiotic (amoxicillin/clavulanic acid)
and an oral corticosteroid to be initiated promptly by
patients in the event of acute exacerbations. This was fol-
lowed by a 20 min telephone call at 3 and 9 months, and a
30 min outpatient visit at 6 and 12 months. Control
patients attended the hospital outpatient clinic at 6 and
12 months where they received usual care from medical
and nursing staff which included symptom assessment,
spirometry where necessary and the prescription of inhalers
and medication when needed.
Health outcomes
For the economic evaluation, the impact of the intervention
on health-related quality of life (HRQoL) was measured
using both the EQ-5D [20] administered at baseline, 6 and
12 months. The EQ-5D is a generic preference-based
measure of health which provides a description of health
using five dimensions (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression) each with 3 levels
of severity and has been shown to be appropriate for use in
patients with COPD [21]. It is recommended by NICE [22]
for use in economic evaluation. The UK social preference
weights for EQ-5D health states were used to obtain single
utility values from the responses at each time point. These
preference weights were derived using the time-trade off
(TTO) technique in a representative sample of the general
population [23]. The area-under-the-curve (AUC) method
[24] was used to estimate patient-specific QALYs accrued
over the 12 month period. This method involves multi-
plying the utility of the patients’ health state at each time
point by the duration of the health state, and then summing
these over the study period. It was assumed that changes in
utility over the time points were linear.
Measuring and valuing costs
In line with guidance from NICE [22] a National Health
Service (NHS) and Personal Social Service (PSS) per-
spective was adopted for the analysis. Only costs relevant
to this perspective were considered. Patient-specific
healthcare resource utilisation was collected prospectively
during the study. This was not COPD specific, unless
otherwise stated. Information on general practitioner (GP)
visits (both scheduled and unscheduled, i.e. emergency)
were obtained via patient completed questionnaires
administered at 6 and 12 months. Information on emer-
gency department (ED) visits, hospital bed days and
exacerbation medication usage (oral steroid and antibiotic
courses) was collected using active follow-up of the
patients’ medical records. Resource use was quantified
and valued in monetary terms by multiplying these units
by unit costs (Table 1) which were obtained from national
sources whenever possible [25, 26] and based on the
financial year 2006/2007 in UK Sterling (£). The inter-
vention costs included the cost of steroid and antibiotic
courses provided to patients to be taken in the event of an
exacerbation (irrespective of whether they were adminis-
tered), the costs of a clinical pharmacist’s time input
(including training), costs of an administrator’s time
input, printing costs and overhead costs. Discounting of
costs and health outcomes was not required as the study
did not exceed 12 months.
Table 1 Unit costs of healthcare resources used
Healthcare resource Unit cost (£, 2006) Details Source of unit cost
GP surgery consultation 25.00 Per 10 min surgery consultation Curtis and Netten (2006)
Hospital pharmacist 40.00 Per hour of patient related activities Curtis and Netten (2006)
ED visit 105.00 Per high cost investigation Curtis and Netten (2006)
Hospital bed day 243.00 Per general inpatient bed day Curtis and Netten (2006)
Oral antibiotic and steroid course 12.33 7 day course of Augmentin and Prednisolone BNF 51 (March 2006)
Hospital administrator 10.88 Per hour NHS employers
Cost of education pack 12.00 Per education pack Estimate
Overheads for outpatient clinical space 2.00 Per minute Belfast Health Social Care Trust
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Data analysis
The economic analyses were carried out on a per protocol
basis therefore they were based only on patients for whom
there was complete resource use and health outcomes data.
Demographic and clinical data were analysed using IBM
SPSS Statistics version 19 to perform Chi-square tests for
categorical data and independent t tests for continuous
data. Resource data is typically skewed and so the under-
lying assumptions of parametric tests of the mean are fre-
quently violated. Since the arithmetic mean is the statistic
of interest for decision making, both parametric t tests and
nonparametric bootstrapping were used as recommended
[27]. STATA version 10 was used to calculate 95% non-
parametric confidence intervals for differential mean costs
and QALYs based on 1,000 bias-corrected, accelerated
bootstrap replications. Imbalance in the mean baseline
utilities between the intervention and control groups was
controlled for by using multiple regression to estimate the
differential QALYs [28].
Economic evaluation involves an incremental analysis
of the costs and consequences of alternative courses of
action, thus the incremental cost-effective ratio (ICER) was
calculated by dividing the mean cost difference between
the intervention and control patients by the mean QALY
difference to establish the cost per QALY gained. To
account for sampling uncertainty in the cost and effect data
used to calculate the ICER, non-parametric bootstrapping
was also performed to generate 1,000 bootstrap replicates
of the ICERs which were then plotted on the cost-effec-
tiveness plane. The resulting scatterplot was used to derive
the cost-effectiveness acceptability curve (CEAC) by cal-
culating the proportion of the replicates which would be
considered cost-effective at various thresholds of willing-
ness-to-pay for an additional QALY.
A series of univariate sensitivity analyses were per-
formed to explore how robust the results were to changes in
the assumptions upon which they were based. We explored
the impact on the cost-effectiveness of the intervention of
variations in; the number of bed days used in each group,
the cost of the self-management and education programme
and the effectiveness of the programme. Finally, multiple
imputation was used to impute missing QALY and cost
data with treatment group, age, gender and COPD severity
incorporated into the multiple linear regression models as
covariates.
Results
The analysis was based only on patients for whom there
was complete resource use and outcomes data for the
intervention period (127 patients: intervention, n = 64;
control, n = 63) were included in the economic analysis
(see Fig. 1). Baseline characteristics were similar across
sociodemographic, clinical and functional variables
(Table 2).
The mean EQ-5D utility scores for the intervention and
usual care group patients at baseline, 6 and 12 months, and
the mean QALYs gained over the study period are pre-
sented in Table 3. A mean differential QALY (controlled
for baseline utility) of 0.065 in favour of the self-man-
agement education programme group was found, but this
was not statistically significant (P = 0.051).
The mean health resource usage per patient over the
study period is presented in Table 4. Statistically signifi-
cantly lower unscheduled GP visits, ED visits, hospital bed
days and oral steroid and antibiotic courses were observed
in the intervention group compared to usual care over the
12 month study period. The main difference related to the
number of hospital bed days with there being 60% fewer
hospital bed days associated with the intervention group.
Patients randomised
(n= 173)
87 patients allocated to
usual care (control group) 
86 patients allocated to 
the intervention group 
Analysed in economic 
evaluation (n=64) 
Excluded from analysis for 
having missing cost or EQ-
5D data (n=7) 
Analysed in economic 
evaluation (n=63) 
Excluded from analysis for 
having missing cost or EQ-
5D data (n=9) 
6 month follow up
Drop out (n=9) 
Lost to follow (n=4) 
Died (n=1) 
Discontinued due to the 
burden of the evaluation 
 (n=4) 
6 month follow up
Drop out (n= 8) 
Lost to follow (n=3) 
Died (n=2) 
Discontinued due to the 
burden of the evaluation 
 (n=3) 
12 month follow up
Drop out (n=7) 
Lost to follow (n=1) 
Died (n=3) 
Discontinued due to the 
burden of the evaluation 
 (n=3) 
12 month follow up 
Drop out (n=6) 
Lost to follow (n=1) 
Died (n=2) 
Discontinued due to the 
burden of the evaluation 
 (n=3) 
Fig. 1 Flow chart showing patient numbers at different stages of the
study
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The mean cost of healthcare resource usage per patient
over the study period is presented in Table 5. This value in
the intervention group was £859.00 compared with
£1,911.77 in the control group. The cost of the interven-
tion-related resources was £381.18 per patient, bringing the
total per-patient cost for the intervention group to
£1,240.18, which is still lower than the total per-patient
cost for the usual care group. Thus a mean differential cost
of -£671.59 was found, indicating a cost saving in the
intervention group. However, this difference was not sta-
tistically significant (P = 0.065).
Cost-utility analysis
Self-management and education was found to be both more
effective and less costly than usual care thus it is the
dominant strategy. In this situation the ICER is not cal-
culated as self-management is clearly good value for
money and furthermore it is inappropriate to interpret the
magnitude of negative ICERs [29]. Uncertainty surround-
ing the estimates of costs and effects is represented on the
cost-effectiveness plane (Fig. 2). The joint density of
incremental costs and effects straddles all four quadrants of
the cost-effectiveness plane, with the majority of the points
lying in the south-east quadrant. This indicates that there is
some degree of uncertainty surrounding both the presence
and the magnitude of cost-savings and effectiveness. The
CEAC summarises this uncertainty. The CEAC (not pre-
sented here) illustrates the probability of the self-manage-
ment education programme being more cost-effective than
usual care at different thresholds of decision makers’
willingness-to-pay (WTP) for a QALY. According to NICE
[30] interventions with an ICER of less than £20,000 per
QALY gained are likely to be considered to be cost-
Table 2 Baseline
characteristics of the patients
 P value calculated using Chi
square test; P \ 0.05 indicates a
statistical significant association
* P value calculated using
independent t test; P \ 0.05
indicates a statistical significant
difference
Characteristics Education self-
management (n = 64)
Usual care
(n = 63)
P value Overall
Age (mean, SD, year) 66.2 (9.8) 66.6 (9.1) 0.67* 66.43 (9.4)
Female (%) 57.8 55.0 0.48 54.0
FEV1 (mean, SD)
Liters 1.2 (0.48) 1.1 (0.50) 0.64* 1.16 (0.5)
Predicted (%) 53.4 (16.0) 51.3 (16.3) 0.45* 52.43 (16.7)
FEV1/FVC 56.5 (9.50) 56.1 (10.8) 0.86* 56.3 (10.2)
Education n (%) 0.91
Primary 16 (25.0) 16 (25.4) 32 (25.2)
Secondary/tertiary 48 (75.0) 47 (74.6) 95 (74.8)
Smoking status n (%) 0.38
Ex-smokers 44 (68.8) 38 (60.3) 82 (64.6)
Current smokers 13 (20.3) 12 (19.0) 25 (19.7)
Never smoked 7 (10.9) 13 (20.7) 20 (15.7)
GOLD classification n (%) 0.32
Mild 6 (9.4) 5 (7.9) 11 (8.7)
Moderate 26 (40.6) 27 (42.8) 53 (41.7)
Severe 32 (50.0) 28 (44.4) 60 (47.2)
Very severe 0 (0.0) 3 (4.9) 3 (2.4)
No. of medication (mean, SD) 8.2 (2.8) 7.8 (4.0) 0.59* 8 (3.5)
Years of diagnosis (mean, SD) 6.7 (5.4) 6.4 (4.6) 0.44* 6.5 (5.0)
Co-morbid conditions n (%) 33 (51.5) 40 (63.5) 0.09 73 (57.4)
Table 3 Mean utilities derived from the EQ-5D, and the associated
mean QALYs
Education and
self-management
(n = 64)
Mean (SD)
Usual care
(n = 63)
Mean (SD)
EQ-5D utilities
Baseline 0.465 (0.301) 0.485 (0.330)
Month 6 0.501 (0.311) 0.416 (0.337)
Month 12 0.499 (0.271) 0.431 (0.280)
Mean QALY 0.491 (0.233) 0.437 (0.271)
Mean differential QALYs
(95% CI)b
0.065a (0.000, 0.128);
P = 0.051
a Adjusted for baseline utility
b 95% non-parametric confidence interval based on 1,000 bias-cor-
rected, accelerated bootstrap replications. If the interval does not
cross zero, the difference is statistically significant
 P value calculated using independent t test; P \ 0.05 indicates a
statistical significant difference
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effective. The probability of the self-management educa-
tion programme being cost-effective at this threshold was
95%. As the threshold increases, a proportion of the
bootstrap re-samples falling into the south-east quadrant
are no longer considered cost-effective, thus the probability
is observed to decrease slightly.
The sensitivity analyses explored the impact of: reduc-
ing the difference observed in the bed days between groups
by 50 and 100% (i.e. no difference), decreasing and
increasing the cost of the intervention by 50%, decreasing
the QALYs gained by 50% and multiply imputing the
missing cost and QALY data instead of excluding patients
Table 4 Healthcare resource utilisation over the study period
Resource use Education self-management
group (n = 64)
Usual care
group (n = 63)
Difference (95% CI)a; P value
Mean (95% CI) Mean (95% CI)
GP consultations (scheduled) 4.27 (3.57, 4.96) 4.84 (4.09, 5.59) -0.57 (-1.55, 0.37); P = 0.260
GP consultations (unscheduled) 1.81 (1.42, 2.20 2.94 (2.31, 3.56) -1.13 (-1.81, -0.43); P = 0.003
ED visits 0.81 (0.47, 1.16) 1.56 (1.05, 2.06) -0.75 (-1.38, -0.21); P = 0.016
Hospital bed days 2.45 (1.27, 3.63) 6.19 (3.71, 8.67) -3.74 (-6.47, -1.32); P = 0.007
Oral steroid and antibiotic courses 3.08 (2.57, 3.59) 4.03 (3.37, 4.69) -0.95 (-1.80, -0.21); P = 0.023
CI confidence interval
a 95% non-parametric confidence interval based on 1,000 bias-corrected, accelerated bootstrap replications. If the interval does not cross zero,
the difference is statistically significant
 P value calculated using independent t test; P \ 0.05 indicates a statistical significant difference
Table 5 Mean NHS costs (£) of healthcare resource use over the 12 month study period
Education and self-management (n = 64) Usual care (n = 63)
Specific healthcare resources Mean (95% CI) Mean (95% CI)
GP consultations (scheduled) 106.64 (89.32, 123.96) 121.03 (102.37, 139.69)
GP consultations (unscheduled) 45.31 (35.62, 55.00) 73.41 (57.87, 88.95)
ED visits 85.31 (49.15, 121.47) 163.33 (110.49, 216.17)
Hospital bed days 596.11 (309.78, 882.44) 1,504.29 (900.66, 2,107.91)
Oral steroid and antibiotic courses 25.62 (19.36, 31.89) 49.71 (41.59, 57.83)
Total 859.00 (539.27, 1,178.72) 1,911.77 (1,262.04, 2,561.51)
Intervention-related resources (per patient)
Hospital Pharmacist inputa 113.22 0
2 day specialist trainingb
Patient training
follow-up phone calls (2)
follow-up outpatient appointments (2)
Oral steroid and antibiotic course 12.33 0
Hospital administrator input 3.63 0
Course materials 12.00 0
Overheadsc 240.00 0
Total 381.18 0
Overall total (healthcare ? intervention) 1,240.18 (920.45,
1,559.90)
645.84 (509.00,
1,180.59)
1,911.77 (1,262.04,
2,561.51)
723.33 (236.99,
2,600.65)
Mean differential costs (95% CIs)d -£671.59 (-£1,584.73, -£68.14); P = 0.065**
a Based on the time input required by the hospital pharmacist as specified in Khdour et al. [18]
b Based on 15 h (2 days) of specialist training at £28 per hour and a throughput of 64
c Based on the total face-to-face contact with the participants (120 min)
d 95% non-parametric confidence interval based on 1,000 bias-corrected, accelerated bootstrap replications
** P value calculated using independent t test; P \ 0.05 indicates a statistical significant difference
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with missing data from the analysis. For the latter, five
replacement values (m = 5) were generated for each
missing cell using multiple linear regression models con-
taining the covariates treatment group, age, gender and
COPD severity. The results showed that the self-manage-
ment education programme for COPD patients remained
the dominant strategy when most key parameters were
varied. The one exception being that when there was no
difference in the number of bed days used between groups,
there was no longer a cost saving. The resulting ICER of
£3,278 per QALY however still remains considerably
lower than the NICE threshold of £20,000 per QALY.
Discussion
This study investigated the economic impact of a pharma-
cist-led self-management education programme for COPD
patients compared with usual care. The intervention pro-
gramme was associated with both a gain in QALYs (0.065)
and a cost saving to the NHS of £671.59 per patient, thus it
was the dominant strategy. Little can be concluded from the
absence of statistically significant differences in cost and
QALYs, since the main RCT was not powered to detect such
differences. Furthermore, in economic evaluations more
focus is now placed on how certain we can be of an inter-
vention’s cost-effectiveness hence the use of cost-effec-
tiveness acceptability curves [31]. Decisions no longer tend
to be based on just the point estimates of cost and effect. The
CEAC indicated that the probability of the intervention
being cost-effective was 95% at a threshold of £20,000/
QALY gained. Sensitivity analyses showed that this finding
was robust to plausible variations in key parameters, thus the
self-management programme for patients with COPD can be
considered highly cost-effective. The current study is an
important addition to the current evidence base as, despite
the considerable financial burden of COPD, relatively few
RCTs have been undertaken which explore the cost-effec-
tiveness of self-management education programmes along-
side the primary research question relating to clinical
effectiveness [14, 16, 17, 32].
The results of the present study demonstrated that a
pharmacy-led education and self-management programme
reduced, on average, hospital bed days by 60% (which
accounted for the majority of the cost difference), emer-
gency department visits by 48% and unscheduled GP visits
by 38%. These findings support those of Bourbeau and
colleagues [9, 16] who reported a 42% reduction in all
hospital days, a 35% reduction in all accident and depart-
ment visits and a 59% reduction in unscheduled physician
visits. Similarly, Gallefoss and Bakke [14] observed
reduction in hospital admission costs, as did Tougaard and
colleagues [32] in a study in the early 1990s. Despite the
fact that the methodological approach differed between
studies, it would appear that cost savings were achieved in
the area of reduced hospitalisation. This is particularly
appropriate as previous research has identified hospitali-
sation for exacerbations as a key cost driver in the man-
agement of COPD [32–37]. One economic evaluation
undertaken alongside an RCT in this area (the COPE self-
management education programme) has presented con-
flicting findings to those reported above. They determined
that the COPE programme was twice as expensive as usual
care, with no discernable benefit (as measured in QALYs)
[17]. However, the COPE programme included a relatively
expensive fitness programme and the economic evaluation
took a societal perspective, thus included costs incurred by
the patients whilst attending the programme.
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Fig. 2 Cost-effectiveness
plane, showing the difference
between education and self-
management and usual care
after 1,000 bootstrap
replications
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This study highlights that one effective method of
reducing the resource use of patients with COPD, in par-
ticular their hospital stay of patients, is to provide them
with sufficient information so that they have the knowledge
and ability to manage their own symptoms. Hospital
pharmacists potentially play an important role in the
delivery of such education programmes as they are in a
primary position to be able to teach the skills needed to
carry out medical regimens specific COPD, or indeed other
diseases.
The health-related quality of life of COPD patients at
baseline as measured by the EQ-5D was considerably
lower than levels reported by Monninkhof et al. [17] (in
patients with similar levels of COPD severity (intervention;
0.465, control; 0.485 vs. intervention; 0.81, control; 0.82).
Furthermore, Rutten-van Mo¨lken et al. [21] report indi-
viduals with a GOLD stage Very Severe average EQ-5D
score of 0.647.
The reason for such low levels self-reported health sta-
tus in our patients cannot be explained easily. The clinical
characteristics of our patients appear to be comparable to
those of the patients in Monninkhof et al.’s study. The low
health status may be due, in part, to all patients being
recruited from a single hospital in Belfast- an area which
has been shown to have a significantly higher proportion of
people reporting problems with health and a lower health
status score than the rest of Northern Ireland [38] as
measured by the EQ-5D. Similarly, findings from the
Northern Ireland Census 2001 [39] showed that 14.3% of
individuals in Belfast reported having poor health com-
pared with 9.7% of people living in the rest of Northern
Ireland. Furthermore the results of a comparative analysis
of self-rated health and mortality in the UK [40] indicated
that, after adjusting for age and gender those in Northern
Ireland were 10% more likely to report not good or fairly
good health (rather than good) than those in England and
Wales. These differences highlight that our results cannot
be readily generalised to other settings. The disparity
between the self-reported health status scores of the COPD
patients in the present study and those in other studies
highlights the drawback of recruiting patients from a single
site. A larger, multisite RCT is required to better under-
stand the nature of self-reported health status in these
patients and to facilitate the generalisability of our results.
The decision to collect only exacerbation related drug
data was influenced by the previous cost-effectiveness
analyses performed in this area. Bourbeau et al. [16] did
not report the cost of pharmaceuticals at all, simply stating
that no differences were observed. Gallefoss and Bakke
[14] report the costs associated with the use of anti-asth-
matics only and Monninkhof et al. [17] reported the cost of
medications for exacerbations only. A pragmatic approach
was therefore applied to this study to reduce the burden of
data collection and yet maintain comparability with pre-
vious studies. We acknowledge however that a change in
health status brought about by the intervention may cause
changes in the medications prescribed outside of the study
(and out of our control).
We performed a complete case analysis of the cost and
QALY data for the primary economic analysis. This is a
naı¨ve method of dealing with censored data and leads to
loss of information and statistical power [29]. Furthermore,
we did not directly compare those patients with complete
data with those who dropped out or had missing data. We
did however perform multiple imputation of this missing
data in the sensitivity analysis found that the intervention
still remained highly cost-effective.
Further studies should attempt to confirm whether our
findings are reproducible in other settings considering the
issues surrounding the low health status of patients. These
studies should also attempt to identify which aspects of the
education and self-management programme were central to
its overall effectiveness by varying, for example, the fre-
quency of outpatient visits, the follow up period, the edu-
cational material provided and the healthcare professional
delivering the programme.
Conclusion
Self-management and education in patients with COPD can
potentially reduce the economic burden of the disease on
the NHS and bring about positive gains in HRQoL, despite
the progressive nature of the disease. The study also
highlighted the important role hospital pharmacists have in
educating patients about medication use. Considering the
wide variety of self-management programmes for patients
with COPD [15], further research is required to establish
which aspects of self-management and education have the
greatest impact on its overall cost-effectiveness.
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